The effects of interferon-beta on portal pressure and serum hepatic fibrotic markers in patients with hepatitis C virus-related cirrhosis: An interim results

DOI Web Site Web Site 1 Citations 49 References
  • Kanazawa Hidenori
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Narahara Yoshiyuki
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Fukuda Takeshi
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Kondoh Chisa
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Harimoto Hirotomo
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Matsushita Yoko
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Kidokoro Hideko
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Katakura Tamaki
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Atsukawa Masanori
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Nakatsuka Katsuhisa
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School
  • Sakamoto Choitsu
    Department of Internal Medicine, Division of Gastroenterology, Nippon Medical School

Bibliographic Information

Other Title
  • インターフェロンβが代償期Ｃ型肝硬変の門脈圧，肝線維化マーカーへ及ぼす影響‐初期成績‐
  • インターフェロンβが代償期C型肝硬変の門脈圧,肝線維化マーカーへ及ぼす影響--初期成績
  • インターフェロン ベータ ガ ダイショウキ Cガタ カンコウヘン ノ モン ミャクアツ カン センイカ マーカー エ オヨボス エイキョウ ショキ セイセキ

Search this article

Abstract

In this prospective cohort study, we evaluated the impacts of interferon-beta on portal pressure and serum hepatic fibrotic markers in 10 patients with compensated hepatitis C virus-related cirrhosis. All patients were treated with 6 MU, daily for 2 weeks and 3 MU, 3 times weekly for 52 weeks. Patients were followed until 1 year after treatment discontinuation. Sustained virological response (SVR) was achieved in 2 patients. Hepatic venous pressure gradient dropped significantly from 17.5±11.8 mmHg to 12.4±4.3 mmHg at the end of treatment. Histological improvement were seen in the staging in 2 patients (from F4 to F3) and in the activity grading in 5 patients. All serum hepatic fibrotic markers (hyaluronic acid, Type III procollagen-N-peptide, type IV collagen, Transforming growth factor-β1) improved significantly during treatment. However, they deteriorated after treatment discontinuation in non-SVR patients. In contrast, these parameters were stable in SVR patients after treatment discontinuation. In conclusion, interferon-beta decreases portal pressure and improves serum hepatic fibrotic markers in patients with compensated hepatitis C virus-related cirrhosis. However, these favorable effects diminish after treatment discontinuation in non-SVR patients.<br>

Journal

  • Kanzo

    Kanzo 52 (1), 7-17, 2011

    The Japan Society of Hepatology

Citations (1)*help

See more

References(49)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top